RecruitingPhase 3NCT06561867

Ticagrelor Versus Cilostazol in Ischemic Stroke

Ticagrelor Versus Cilostazol in Moderate and Moderate-to-severe Ischemic Stroke, a Randomized Controlled Trial

Sponsor

Kafrelsheikh University

Enrollment

900 participants

Start Date

Aug 30, 2024

Study Type

INTERVENTIONAL

Conditions

Ischemic Stroke

Summary

Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever moderate and moderate to severe ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cilostazol 100 MG and a drug called Ticagrelor 90 MG for people with ischemic stroke. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTicagrelor 90 MG

Efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects

DRUGCilostazol 100 MG

Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.